导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.43% | 2927/4773 |
| 近一周 | -2.30% | 1720/5462 |
| 近一月 | -4.26% | 2336/5421 |
| 近一季 | -8.02% | 2640/5209 |
| 近半年 | -3.36% | 2185/4920 |
| 近一年 | -0.06% | 2657/4366 |
| 近两年 | 45.32% | 1631/2954 |
| 近三年 | 27.09% | 1180/2253 |
| 成立以来 | 13.78% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.77% 3408/4961 |
12.20% 2210/5312 |
- - |
- - |
| 2025 | 20.10% 2149/4813 |
-1.04% 2552/3635 |
2.30% 1665/4076 |
18.62% 2270/4524 |
0.01% 2287/4813 |
| 2024 | 16.83% 754/3463 |
2.89% 677/2808 |
-1.19% 969/3014 |
16.53% 1427/3129 |
-1.39% 1681/3463 |
| 2023 | -9.64% 1208/2656 |
4.48% 943/2280 |
-4.06% 1030/2385 |
-3.37% 908/2515 |
-6.71% 1887/2655 |
| 2022 | -20.18% 943/2207 |
-14.66% 982/1919 |
6.99% 558/2016 |
-14.10% 1025/2113 |
1.79% 1142/2208 |
| 2021 | 0.67% 708/1822 |
-2.21% 598/1255 |
6.42% 753/1330 |
-4.71% 730/1466 |
1.52% 891/1822 |
| 2020 | - - |
- - |
- - |
- - |
13.56% 352/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 华安沪深300ETF联接A VS. 长安沪深300非周期A(740101) |